| This meeting was only intended for healthcare professionals from the UK and Ireland. This meeting was organised and funded by Teva and included mention of Teva product(s). Prescribing Information was available at the meeting and is available in the links below. |
| Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0)207 540 7117, or email uk.safety@tevauk.com. |
Headaches and hormones: understanding the relationships between female hormones and migraines
From Head Start's Annual Meeting, June 2024
Understanding the relationships between female hormones and migraines with Dr Rebecca Walker
Dr Rebecca Walker explains in her presentation why women are more susceptible to migraines and the role of hormone therapy in migraine management.
She underlines how migraine is not a contraindication to hormone replacement therapy (HRT), but noted how the impact of HRT on migraine is variable.01
Dr Walker also stresses the importance of aiming for a stable hormonal environment during perimenopause, recommending the use of the lowest effective dose of oestradiol to control symptoms.01
Abbreviations
CGRP, calcitonin gene-related peptide; FASPS2, familial advanced sleep phase syndrome-2; HRT, hormone replacement therapy; ICS, integrated care systems; NICE, National Institute for Health and Care Excellence.
Discover more about Head Start's Annual Meeting
Prescribing Information
References
-
Back to contents.
MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reproductive Health. 2018;24(1):11-18. doi:10.1177/2053369117731172
This meeting was open to HCPs from the UK and Ireland with an interest in headache and migraine. This meeting was organised and funded by Teva.
Registered in England No. 302461. Registered office: Teva UK Limited, Ridings Point, Whistler Drive, Castleford, West Yorkshire, WF10 5HX
+44 (0) 1977 628500 | www.tevauk.com | Copyright © 2024 Teva UK Limited
Adverse events should be reported: Reporting forms and information can be found at www.mhra.gov.uk/yellowcard (UK) or www.hpra.ie (ROI). Adverse events should also be reported to Teva using the Reporting Side Effects Form or telephone +44 (0) 207 540 7117, or email uk.safety@tevauk.com.
Privacy Policy | Pharmacovigilance Privacy Policy | Terms and Conditions | Accessibility | Reporting Adverse Events